Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study
出版年份 2018 全文链接
标题
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study
作者
关键词
CD8, CD4/CD8 ratio, Chronic inflammation, Monotherapy, Dual therapy
出版物
BMC Medicine
Volume 16, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-05-25
DOI
10.1186/s12916-018-1046-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
- (2018) Josep M Llibre et al. LANCET
- Brief Report
- (2017) Nicola Gianotti et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial
- (2017) Francesca Lombardi et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
- (2017) Pedro Cahn et al. Journal of the International AIDS Society
- A Low Peripheral Blood CD4/CD8 Ratio Is Associated with Pulmonary Emphysema in HIV
- (2017) Matthew Triplette et al. PLoS One
- Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers
- (2017) Fanny Chereau et al. PLoS One
- Determinants of a Low CD4/CD8 Ratio in HIV-1–Infected Individuals Despite Long-term Viral Suppression
- (2016) Fabienne Caby et al. CLINICAL INFECTIOUS DISEASES
- Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial
- (2016) Lars Oddershede et al. PHARMACOECONOMICS
- Low CD4/CD8 Ratio Is Associated with Non AIDS-Defining Cancers in Patients on Antiretroviral Therapy: ANRS CO8 (Aproco/Copilote) Prospective Cohort Study
- (2016) Mariam Noelie Hema et al. PLoS One
- Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
- (2015) José A Perez-Molina et al. LANCET INFECTIOUS DISEASES
- CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study
- (2015) Cristina Mussini et al. Lancet HIV
- Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 Ratio
- (2014) Annalisa Saracino et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Course and Clinical Significance of CD8+T-Cell Counts in a Large Cohort of HIV-Infected Individuals
- (2014) Marie Helleberg et al. JOURNAL OF INFECTIOUS DISEASES
- Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration
- (2014) Colette J Smith et al. LANCET
- Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial
- (2014) François Raffi et al. LANCET
- Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial
- (2014) Pedro Cahn et al. LANCET INFECTIOUS DISEASES
- HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality
- (2014) Sergio Serrano-Villar et al. PLoS Pathogens
- Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
- (2013) Stefano Rusconi et al. PLoS One
- The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load
- (2012) JR Arribas et al. HIV MEDICINE
- Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 Weeks
- (2012) Sidonie Lambert-Niclot et al. PLoS One
- Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study
- (2011) M. A. Valantin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started